Design and synthesis of novel prodrugs of 2'-deoxy-2'-methylidenecytidine activated by membrane dipeptidase overexpressed in tumor tissues

Bioorg Med Chem Lett. 2007 Apr 15;17(8):2241-5. doi: 10.1016/j.bmcl.2007.01.066. Epub 2007 Jan 27.

Abstract

DNA microarray analysis comparing human tumor tissues with normal tissues including hematopoietic progenitor cells resulted in identification of membrane dipeptidase as a prodrug activation enzyme. Novel prodrugs of 2'-deoxy-2'-methylidenecytidine (DMDC) including compound 23 that are activated by membrane dipeptidase (MDP) preferentially in tumor tissue were designed and synthesized to generate the active drug, DMDC, after hydrolysis of the dipeptide bond followed by spontaneous cyclization of the promoiety.

MeSH terms

  • Antineoplastic Agents / chemical synthesis*
  • Antineoplastic Agents / pharmacokinetics
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / chemistry
  • Deoxycytidine / metabolism
  • Deoxycytidine / pharmacokinetics
  • Dipeptidases / genetics
  • Dipeptidases / metabolism*
  • Drug Design*
  • Gene Expression Regulation, Neoplastic*
  • Humans
  • Hydrolysis
  • Membrane Proteins
  • Neoplasm Proteins / metabolism
  • Oligonucleotide Array Sequence Analysis
  • Prodrugs / chemical synthesis*
  • Prodrugs / metabolism*
  • Structure-Activity Relationship
  • Tumor Cells, Cultured

Substances

  • Antineoplastic Agents
  • Membrane Proteins
  • Neoplasm Proteins
  • Prodrugs
  • Deoxycytidine
  • Dipeptidases
  • dipeptidase
  • 2'-deoxy-2'-methylenecytidine